Antibodies to desmoglein 1 and 3, and the clinical phenotype of pemphigus vulgaris

Journal of the American Academy of Dermatology

Volumn 48, Issue 6, 2003, Pages 976-977

  Jamora, Maria Jasmin J ^b   Jiao, Diane ^b   Bystryn, Jean Claude ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; DESMOGLEIN 1; DESMOGLEIN 1 ANTIBODY; DESMOGLEIN 3; DESMOGLEIN 3 ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; MOUTH LESION; PEMPHIGUS VULGARIS; PHENOTYPE; PRIORITY JOURNAL; SKIN DEFECT;

EID: 0038792648     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2003.438     Document Type: Article

References (5)

1. Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999;40:167-70.
2. Komai A, Amagai M, Ishii K, Nishikawa T, Chorzelski T, Matsuo I, et al. The clinical transition between pemphigus foliaceus and pemphigus vulgaris correlates well with the changes in autoantibody profile assessed by an enzyme-linked immunosorbent assay. Br J Dermatol 2001;144:1177-82.
3. Harman KE, Seed PT, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol 2001;144:775-80.
4. Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999;103:461-8.
5. Ioannides D, Hytioglous P, Phelps RG, Bystryn JC. Regional variation in the expression of pemphigus foliaceus, pemphigus erythematosus and pemphigus vulgaris antigens in human skin. J Invest Dermatol 1991;96:159-61.